Randomized Clinical Trials in Breast Cancer

Surgical Oncology Clinics of North America

Volumn 19, Issue 1, 2010, Pages 33-58

  Crago, Aimee M ^a   Azu, Michelle ^a   Tierney, Shannon ^a   Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Breast conserving therapy; Literature review; Randomized clinical trials

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; RALOXIFENE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70449365388     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.09.003     Document Type: Review

References (46)

1. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (2002) 567-575
2. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
3. Poggi M.M., Danforth D.N., Sciuto L.C., et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98 (2003) 697-702
4. van Dongen J.A., Voogd A.C., Fentiman I.S., et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 92 (2000) 1143-1150
5. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
6. Clarke M., Collins R., Darby S., et al., Early Breast Cancer Trialists' Collaborative Group (EBCTG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2006) 2087-2106
7. Veronesi U., Paganelli G., Viale G., et al. Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomized controlled trial. Lancet Oncol 6 (2006) 983-990
8. Giuliano A., Kirgan D., Guenther J., et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220 (1994) 391-401
9. Krag D.N., Anderson S.J., Julian T.B., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8 (2007) 881-888
10. Posther K.E., McCall L.M., Blumencranz P.W., et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg 242 (2005) 593-599
11. Mansel R.E., Fallowfield L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98 (2006) 599-609
12. Zavagno G., De Salvo G.L., Scalco G., et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247 (2008) 207-213
13. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10 (2003) 1140-1151
14. Fisher B., Land S., Mamounas E., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28 (2001) 400-418
15. Fisher B., Costantino J., Redmond C., et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328 (1993) 1581-1586
16. Emdin S.O., Granstrand B., Ringberg A., et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45 (2006) 536-543
17. Bijker N., Meijnen P., Peterse J.L., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24 (2006) 3381-3387
18. Houghton J., George W.D., Cuzick J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362 (2003) 95-102
19. Allred D.C., Bryant J., Land S., et al. Estrogen expression as a predictive marker of the effectiveness of tamoxifen in the treatment of intraductal breast cancer: findings of the NSABP Protocol B-24 [abstract]. Breast Cancer Res Treat 76 (2002) S36
20. Ragaz J., Ollivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97 (2005) 116-126
21. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337 (1997) 949-955
22. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
23. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: and overview of the randomised trials. Lancet 365 (2005) 1687-1717
24. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 (2003) 976
25. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
26. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483
27. Rastogi P., Anderson S.J., Bear H.D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26 (2008) 778-785
28. Mauri D.N., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 (2005) 188-194
29. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
30. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
31. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809
32. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 22 (2005) 1652-1662
33. Powles T.J., Ashley S., Tidy A., et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (2007) 283-290
34. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (2007) 272-282
35. Veronesi U., Maisonneuve P., Rotmensz N., et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (2007) 727-737
36. Cuzick J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer 36 (2000) 1298
37. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727
38. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
39. Peto R. The worldwide overview: new results for systemic adjuvant therapies. Breast Cancer Res 106 (2007) S5
40. Forbes J.F., Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
41. Crivellari D., Sun Z., Coates A.S., et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26 (2008) 1972-1979
42. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
43. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455
44. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 26 (2008) 1965-1971
45. Muss H.B., Tu D., Ingle J.N., et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26 (2008) 1956
46. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802